#United States #New York #Pomerantz Law #Investors Alert #Aquestive Therapeutics

Pomerantz Law Firm Takes Action on Behalf of Investors in Aquestive Therapeutics

Pomerantz LLP has initiated an investigation regarding potential claims from investors associated with Aquestive Therapeutics, Inc. (NASDAQ: AQST). Recent developments have raised concerns about the company’s adherence to lawful business practices, specifically surrounding securities fraud allegations. Investors who have been affected by these issues are encouraged to reach out to attorney Danielle Peyton at Pomerantz for further assistance.

Investigation Context

The investigation stems from alarming announcements made by Aquestive's leadership on January 9, 2026, when the company's President and CEO revealed that the FDA identified significant deficiencies in the New Drug Application (NDA) for its product, Anaphylm. The notification explicitly stated that these deficiencies hindered any discussions regarding labeling and post-marketing commitments for the drug. Unfortunately, the notification did not elaborate on the specifics of the deficiencies, adding to investor uncertainty.

In the aftermath of this disclosure, the stock price of Aquestive took a dramatic hit, dropping by $2.30 per share, which corresponds to a staggering 37.04% decrease, closing at $3.91 per share on the same day. Such a plummet invariably raises concerns regarding the transparency and operational conduct of the company, prompting investors to question whether they have been misled regarding the drug’s market viability and the company's financial health.

Pomerantz LLP: A Track Record of Advocacy

Pomerantz LLP, recognized as one of the leading law firms in corporate, securities, and antitrust class litigation, takes pride in its extensive experience and success in advocating for victims of securities fraud and corporate misconduct. Founded by Abraham L. Pomerantz, the firm specializes in representing investors and has consistently fought for their rights over the past 85 years. The firm is credited with recovering substantial damage awards for its clients, underscoring its commitment to justice.

As part of its ongoing mission, Pomerantz is investigating claims from investors to determine if the officers and directors of Aquestive knowingly engaged in unlawful business practices, thereby misleading shareholders. The firm’s seasoned attorneys are dedicated to ensuring that corporate misconduct does not go unchecked, and they are prepared to lead the charge on behalf of defrauded investors.

Call to Action for Affected Investors

Investors who believe they have been affected by the alleged deficiencies and resulting stock price drop are strongly advised to take action. Pomerantz provides a platform for individuals to join a class action suit, which may hold the company accountable for its potential missteps. Interested parties should not hesitate to make contact with Danielle Peyton via email at [email protected] or by phone at 646-581-9980, ext. 7980 for detailed information on how to proceed.

The outcome of this investigation could have significant repercussions for both the company and its investors. As such, affected investors should remain vigilant and informed about any developments. Pomerantz is ready to assist in navigating this complex legal landscape, ensuring that investors are not left to handle these challenges alone. Transparency and justice are crucial in these proceedings, and Pomerantz is committed to upholding these values.

Conclusion

As this investigation unfolds, the emphasis will remain on scrutinizing the practices within Aquestive Therapeutics. With the vital role of the FDA in ensuring drug safety and efficacy, any deficiencies noted in the NDA raise serious questions about corporate governance and the impact on shareholder value. Stakeholders in the healthcare sector, along with the watching public, will undoubtedly be paying close attention to the developments stemming from this situation. Investors looking to reclaim their rights and seek justice should act swiftly and engage legal counsel to navigate this evolving scenario.